Page 3 - ஃபைப்ரோஸிஸ் புதியது ஜீலாந்து News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from ஃபைப்ரோஸிஸ் புதியது ஜீலாந்து. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In ஃபைப்ரோஸிஸ் புதியது ஜீலாந்து Today - Breaking & Trending Today

Welcome To IANS Live - SCIENCE - Novel gene editor to correct disease-causing mutations

One in seventeen people in the world suffers from some type of genetic disorder. ....

India Private , News Service , C Tog Base Editor , All Rights , இந்தியா ப்ரைவேட் , செய்தி சேவை , அனைத்தும் உரிமைகள் ,

Welcome To IANS Live - SCIENCE AND TECHNOLOGY - Novel gene editor to correct disease-causing mutations

One in seventeen people in the world suffers from some type of genetic disorder. ....

India Private , News Service , C Tog Base Editor , All Rights , இந்தியா ப்ரைவேட் , செய்தி சேவை , அனைத்தும் உரிமைகள் ,

Researchers discover new molecular target that could treat idiopathic pulmonary fibrosis

Researchers discover new molecular target that could treat idiopathic pulmonary fibrosis
Researchers at the University of Alabama at Birmingham have identified a new molecular target that could potentially treat the deadly, aging-related lung disease idiopathic pulmonary fibrosis (IPF). The study, which will be published March 10 in the
Journal of Experimental Medicine (
JEM), suggests that targeting a protein called MDM4 could prevent respiratory failure by initiating a genetic program that removes scar tissue from the lungs.
IPF is characterized by the accumulation of scar tissue that stiffens the lungs and makes it difficult for patients to breathe and get sufficient oxygen into their blood. Though the causes of IPF remain unclear, age is a significant risk factor: the disease is estimated to affect 1 in 200 US adults over the age of 70. ....

Emily Henderson , Department Of Medicine , University Of Alabama At Birmingham , Experimental Medicine , Pulmonary Fibrosis , Idiopathic Pulmonary Fibrosis , Lung Disease , எமிலி ஹென்டர்சன் , துறை ஆஃப் மருந்து , பல்கலைக்கழகம் ஆஃப் அலபாமா இல் பர்மிங்காம் , சோதனை மருந்து , நுரையீரல் ஃபைப்ரோஸிஸ் , நுரையீரல் நோய் ,

Novel CRISPR-based gene editor developed to correct mutations that cause genetic disorders

Novel CRISPR-based gene editor developed to correct mutations that cause genetic disorders
A team of researchers from the Agency for Science, Technology and Research s (A STAR) Genome Institute of Singapore (GIS) have developed a CRISPR-based gene editor, C-to-G Base Editor (CGBE), to correct mutations that cause genetic disorders. Their research was published in
Nature Communications on 2 March 2021.
One in seventeen people in the world suffers from some type of genetic disorder. Chances are, you or someone you know - a relative, friend, or colleague - is one of approximately 450 million people affected worldwide. Mutations responsible for these disorders can be caused by multiple mutagens - from sunlight to spontaneous errors in your cells. The most common mutation by far is the single-based substitution, in which a single-base in the DNA (such as G) is replaced by another base (such as C). Countless cystic fibrosis patients worldwide have C instead of G, leading to ....

Kwei Leong , Emily Henderson , Agency For Science , Genome Institute Of Singapore , Nature Communications , Senior Research Scientist , Genome Institute , C Tog Base Editor , Chew Wei Leong , Young Scientist Award , Patrick Tan , Executive Director , Cystic Fibrosis , Genetic Disorder , வெய் லியோங் , எமிலி ஹென்டர்சன் , மரபணு நிறுவனம் ஆஃப் சிங்கப்பூர் , இயற்கை தகவல்தொடர்புகள் , மூத்தவர் ஆராய்ச்சி விஞ்ஞானி , மரபணு நிறுவனம் , மெல் வெய் லியோங் , இளம் விஞ்ஞானி விருது , பேட்ரிக் பழுப்பு , நிர்வாகி இயக்குனர் , சிஸ்டிக் ஃபைப்ரோஸிஸ் , ஜெநெடிக் கோளாறு ,

IQWiG's new threshold proven feasible in practice for early benefit assessments of drugs

IQWiG s new threshold proven feasible in practice for early benefit assessments of drugs
Current examples prove the feasibility of the 15 percent threshold newly defined by IQWiG for the acceptance of responder analyses in early benefit assessments of drugs.
In order to show the clinical relevance of a difference between two treatment alternatives, in recent years, the manufacturer dossiers submitted in early benefit assessments of new drugs have increasingly contained responder analyses for patient-relevant outcomes.
In such analyses, it is investigated whether the proportion of patients experiencing a noticeable change in the respective outcome differs between the two treatment groups in a study. ....

Katrin Nink , Emily Henderson , Iqwig Drug Assessment Department , General Methods , Drug Assessment Department , Drug Assessment , Breast Cancer , Cystic Fibrosis , Psoriatic Arthritis , எமிலி ஹென்டர்சன் , ஜநரல் முறைகள் , மருந்து மதிப்பீடு துறை , மருந்து மதிப்பீடு , மார்பக புற்றுநோய் , சிஸ்டிக் ஃபைப்ரோஸிஸ் , சொரியாடிக் கீல்வாதம் ,